EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

MyoMed205 Counteracts Titin Hyperphosphorylation and the Expression of Contraction‐Regulating Proteins in a Rat Model of HFpEF

Beatrice Vahle iD, Antje Schauer, Antje Augstein, Maria-Elisa Prieto Jarabo, Janet Friedrich, Peggy Barthel, Anita Männel, Norman Mangner, Siegfried Labeit, T Scott Bowen, Axel Linke, Volker Adams iD

Journal of Cachexia, Sarcopenia and Muscle · 2025

DOI: 10.1002/jcsm.13843 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2025. Verfasst von Beatrice Vahle und 11 weiteren Autor:innen. Beteiligte Einrichtung: Heart Center, University Clinic, Department of Internal Medicine, Laboratory of Molecular and Experimental Cardiology, University of Technology Dresd…. Hauptthemen laut MEDLINE: Connectin, Heart Failure, Muscle Contraction. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: DZHK (German Center for Cardiovascular Research), Deutsches Zentrum für Herz-Kreislaufforschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Heart failure with preserved ejection fraction (HFpEF) is associated with exercise intolerance, accompanied by alterations in the peripheral skeletal muscle (SKM). We have recently shown that titin, a giant sarcomere protein, is hyperphosphorylated in HFpEF. MuRF1 is a muscle‐specific ubiquitin E3‐ligase that interacts with titin. Blocking this interaction via small molecules (MyoMed205) can improve muscle function and mitochondrial activity in HFpEF. This study aimed to investigate the impact of MyoMed205 on titin phosphorylation and its association with changes in muscle structure and function.

Methods

Obese ZSF1 rats with established HFpEF received rat chow with ( n = 15) or without ( n = 15) MyoMed205 and were compared with lean littermates ( n = 15), serving as controls. After 12 weeks, in vitro SKM force, atrophy and titin—as well as contractile protein expression—were evaluated (soleus and extensor digitorum longus [EDL]). Statistical analysis was performed via multiple unpaired t ‐test or one‐way ANOVA.

Results

In HFpEF, titin hyperphosphorylation by 13% in the EDL ( p = 0.09) and 14% ( p = 0.03) in the soleus muscle was evident. This hyperphosphorylation was driven in part by an increase in S11878 phosphorylation (EDL: +68%, p = 0.004; Sol: +23.8%, p = 0.03), which was linked to myofiber atrophy ( r = −0.68, p = 0.006) and a decline in maximal specific muscle force ( r = −0.54, p = 0.008). In the EDL, significant changes in protein expression related to atrophy (MuRF1 [+24.9%, p = 0.02], GDF8 [+20.6%, p = 0.09]) and calcium handling (slow troponin C [−46%, p = 0.02], fast troponin I [+35.8%, p = 0.02]) were found in HFpEF. All of the above‐mentioned effects in HFpEF were almost completely abolished by MyoMed205 treatment, and significantly elevated titin expression was visible (+19.7%, p con = 0.04, p HFpEF = 0.01).

Conclusions

Titin hyperphosphorylation may negatively impact skeletal muscle integrity and function in HFpEF. MyoMed205 reduced titin hyperphosphorylation and was associated with preserved skeletal muscle function and mass. Further studies are necessary to confirm the direct role of titin hyperphosphorylation on muscle function and to evaluate the therapeutic potential of MyoMed205 in HFpEF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ConnectinHeart FailureMuscle ContractionAnimalsRatsPhosphorylationDisease Models, AnimalMuscle, SkeletalMaleMuscle ProteinsUbiquitin-Protein LigasesStroke Volume

Stichwörter der Autor:innen

HFpEFMuRF1MyoMed205ZSF1atrophycontractile proteinssarcopeniaskeletal muscle functiontitin

Substanzen

ConnectinMuscle ProteinsTtn protein, ratUbiquitin-Protein Ligases

Autor:innen und Institutionen

  • Heart Center, University Clinic, Department of Internal Medicine, Laboratory of Molecular and Experimental Cardiology, University of Technology Dresden, Dresden, Germany.
  • DZHK Partner Site Mannheim-Heidelberg, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
  • Myomedix GmbH, Neckargemünd, Germany.
  • School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Leeds, UK.

ORCID-Profile: Beatrice Vahle, Volker Adams

Förderung

  • DZHK (German Center for Cardiovascular Research)
  • Deutsches Zentrum für Herz-Kreislaufforschung

Zitieren

APA

Vahle, B., Schauer, A., Augstein, A., Jarabo, M. P., Friedrich, J., Barthel, P., Männel, A., Mangner, N., Labeit, S., Bowen, T. S., Linke, A., & Adams, V. (2025). MyoMed205 Counteracts Titin Hyperphosphorylation and the Expression of Contraction‐Regulating Proteins in a Rat Model of HFpEF. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.13843

Vancouver

Vahle B, Schauer A, Augstein A, Jarabo MP, Friedrich J, Barthel P, et al. MyoMed205 Counteracts Titin Hyperphosphorylation and the Expression of Contraction‐Regulating Proteins in a Rat Model of HFpEF. Journal of Cachexia, Sarcopenia and Muscle. 2025. doi:10.1002/jcsm.13843

BibTeX
@article{Vahle2025,
  author = {Vahle, Beatrice and Schauer, Antje and Augstein, Antje and Jarabo, Maria-Elisa Prieto and Friedrich, Janet and Barthel, Peggy and Männel, Anita and Mangner, Norman and Labeit, Siegfried and Bowen, T Scott and Linke, Axel and Adams, Volker},
  title = {MyoMed205 Counteracts Titin Hyperphosphorylation and the Expression of Contraction‐Regulating Proteins in a Rat Model of HFpEF},
  journal = {Journal of Cachexia, Sarcopenia and Muscle},
  year = {2025},
  doi = {10.1002/jcsm.13843}
}
Kostenlos starten →